Elutia Q3 revenue falls short of estimates, gross margin improves

Reuters

2025/11/07

<a href="https://laohu8.com/S/ELUT">Elutia</a> Q3 revenue falls short of estimates, gross margin improves

Overview

Elutia Q3 revenue missed analyst expectations
Company completed $88 mln sale of BioEnvelope business to Boston Scientific
Gross margin improved to 55.8% from 48.9% in Q3 2024

Outlook

Elutia anticipates FDA clearance for NXT-41x base matrix in 2H26
Company expects drug-eluting NXT-41x version clearance in 1H27

Result Drivers

BIOENVELOPE SALE - Sale of BioEnvelope business to Boston Scientific for $88 mln used to eliminate debt and fund NXT-41x development
NXT-41X DEVELOPMENT - Advancing NXT-41x to address infections in plastic and reconstructive surgery, targeting a $1.5 bln market

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Miss	$3.32 mln	$6.65 mln (2 Analysts)
Q3 Net Income		-$3.87 mln
Q3 Gross Profit		$1.85 mln
Q3 Income From Operations		-$5.21 mln
Q3 Operating Expenses		$7.06 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Elutia Inc is $4.00, about 76% above its November 5 closing price of $0.96

Press Release: ID:nGNX4njjLm

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581049217"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581049217\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581049217?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 06:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581049217","market":"fut","top_or_hot":-1,"title":"Elutia Q3 revenue falls short of estimates, gross margin improves","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ELUT\">Elutia</a> Q3 revenue falls short of estimates, gross margin improves</title></head><body><p><span>Overview</span></p><ul><li><p>Elutia Q3 revenue missed analyst expectations</p></li><li><p>Company completed $88 mln sale of BioEnvelope business to Boston Scientific</p></li><li><p>Gross margin improved to 55.8% from 48.9% in Q3 2024</p></li></ul><p><span>Outlook</span></p><ul><li><p>Elutia anticipates FDA clearance for NXT-41x base matrix in 2H26</p></li><li><p>Company expects drug-eluting NXT-41x version clearance in 1H27</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>BIOENVELOPE SALE - Sale of BioEnvelope business to Boston Scientific for $88 mln used to eliminate debt and fund NXT-41x development</p></li><li><p>NXT-41X DEVELOPMENT - Advancing NXT-41x to address infections in plastic and reconstructive surgery, targeting a $1.5 bln market</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$3.32 mln</p></td><td><p>$6.65 mln (2 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$3.87 mln</p></td><td></td></tr><tr><td><p>Q3 Gross Profit</p></td><td></td><td><p>$1.85 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$5.21 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$7.06 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Elutia Inc is $4.00, about 76% above its November 5 closing price of $0.96</p></li></ul><p>Press Release: <span>ID:nGNX4njjLm</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elutia Q3 revenue falls short of estimates, gross margin improves</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElutia Q3 revenue falls short of estimates, gross margin improves\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-07 06:32</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ELUT\">Elutia</a> Q3 revenue falls short of estimates, gross margin improves</title></head><body><p><span>Overview</span></p><ul><li><p>Elutia Q3 revenue missed analyst expectations</p></li><li><p>Company completed $88 mln sale of BioEnvelope business to Boston Scientific</p></li><li><p>Gross margin improved to 55.8% from 48.9% in Q3 2024</p></li></ul><p><span>Outlook</span></p><ul><li><p>Elutia anticipates FDA clearance for NXT-41x base matrix in 2H26</p></li><li><p>Company expects drug-eluting NXT-41x version clearance in 1H27</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>BIOENVELOPE SALE - Sale of BioEnvelope business to Boston Scientific for $88 mln used to eliminate debt and fund NXT-41x development</p></li><li><p>NXT-41X DEVELOPMENT - Advancing NXT-41x to address infections in plastic and reconstructive surgery, targeting a $1.5 bln market</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$3.32 mln</p></td><td><p>$6.65 mln (2 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$3.87 mln</p></td><td></td></tr><tr><td><p>Q3 Gross Profit</p></td><td></td><td><p>$1.85 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$5.21 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$7.06 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Elutia Inc is $4.00, about 76% above its November 5 closing price of $0.96</p></li></ul><p>Press Release: <span>ID:nGNX4njjLm</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0011850046.USD","symbol_name":"貝萊德全球長線股票 A2 USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1MM:1","article_id":"2581049217","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581049217","pubTimestamp":1762468330,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Elutia Q3 revenue falls short of estimates, gross margin improvesOverviewElutia Q3 revenue missed analyst expectationsCompany completed $88 mln sale of BioEnvelope business to Boston ScientificGross m","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0011850046.USD":"贝莱德全球长线股票 A2 USD","ELUT":"Elutia","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","BK4082":"医疗保健设备","LU0882574055.USD":"富达全球健康医疗A ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BSX":"波士顿科学","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4588":"碎股","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","BK4581":"高盛持仓","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC"},"translate_title":"Elutia第三季度收入低于预期，毛利率改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":0.9,"ELUT":0.9},"content_text":"Elutia Q3 revenue falls short of estimates, gross margin improvesOverviewElutia Q3 revenue missed analyst expectationsCompany completed $88 mln sale of BioEnvelope business to Boston ScientificGross margin improved to 55.8% from 48.9% in Q3 2024OutlookElutia anticipates FDA clearance for NXT-41x base matrix in 2H26Company expects drug-eluting NXT-41x version clearance in 1H27Result DriversBIOENVELOPE SALE - Sale of BioEnvelope business to Boston Scientific for $88 mln used to eliminate debt and fund NXT-41x developmentNXT-41X DEVELOPMENT - Advancing NXT-41x to address infections in plastic and reconstructive surgery, targeting a $1.5 bln marketKey DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueMiss$3.32 mln$6.65 mln (2 Analysts)Q3 Net Income-$3.87 mlnQ3 Gross Profit$1.85 mlnQ3 Income From Operations-$5.21 mlnQ3 Operating Expenses$7.06 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for Elutia Inc is $4.00, about 76% above its November 5 closing price of $0.96Press Release: ID:nGNX4njjLmFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}